The Australian Pharmaceutical market, valued at USD 12 billion, is a market of strategic focus for Lupin, with generics accounting for 20% of the total market. In a strategic move to strengthen our position in the Australian market, Lupin increased its stake in Generic Health Pty. Ltd. to 76.7% from 49.9%, thus gaining management control. Rapidly growing OTC markets combined with factors like National Health Insurance coverage make this market a very lucrative generic opportunity. It is estimated that over half of the Top 100 selling prescription medicines in Australia are expected to come off patent in the next 4 years. With its wide range of quality generic products and OTC products, Generic Health presents a strategic fit to Lupin’s growth aspirations in Australia.

For more information log on to: www.generichealth.com.au